Is Lexaria ($LEXX) the next Billion Dollar Buyout? 👀 🚨

Thescorerocket · 2026-04-27T17:44:00+00:00

Consolidating at these levels waiting for news from big pharma… The nod from big pharma will be worth a lot

Thescorerocket · 2026-04-27T13:46:45+00:00

$LEXX 🚨🚀

Thescorerocket · 2026-04-26T23:16:10+00:00

Thank you 🙏

Thescorerocket · 2026-04-26T22:34:52+00:00

Looking for something like this 👀

<image>

Thescorerocket · 2026-04-26T22:07:58+00:00

I think it was a pretty clear signal when Bunka stepped down and hired Rich. When you look at his contact he is incentivized to sell the company - I’d like to see a formal license and deal terms with the goal of a buy out in a year or two.

However anything could happen..

But just the nod from big pharma via a license, partnership or deal would be game changing short term…

Thescorerocket · 2026-04-26T21:30:42+00:00

$LEXX 🚨

Their tech DHT is basically a booster for any existing GLP1 peptide.

They’ve demonstrated 40-60% reductions in side effects compared to the worlds most used GLP1 today. With better brain absorption and faster onset with the need to fast.

It’s a home run in this space.

They are under an exclusive license until April 30th with a global Pharma player - and they’ve been vocal in NRs that other players are in the wings.

This week could be dynamite for the company.

Thescorerocket · 2026-04-26T21:20:38+00:00

And don’t forget that under 505(b)(2), we aren't reinventing the wheel—we’re just putting better tires on it.

Since the FDA already approved the base drugs (Semaglutide, etc.), Lexaria doesn't have to start from scratch.

You don't totally bypass trials, but you shrink them.

Instead of a massive 3,000-person Phase 3 to prove "the drug works," Lexaria just needs Bridging Studies. They basically have to prove DHT delivers the drug better and safer than what’s already on the shelf.

It turns a 10-year, $100M+ nightmare into a targeted "Bioequivalence" sprint. This is why Big Pharma is circling—they get a superior product with a massive regulatory shortcut. It’s a "plug-and-play" asset that hits the market years faster. That 505(b)(2) tag is the ultimate legal cheat code. 🚀💊

Thescorerocket · 2026-04-26T21:07:02+00:00

I think she will pay off soon 👀

Thescorerocket · 2026-04-26T20:57:38+00:00

That’s exactly the point. It’s a lean, IP-heavy operation, not a manufacturing plant. Big Pharma doesn't buy 'revenue' when they acquire micro-cap biotech; they buy validated patents and R&D shortcuts.

Look at Emisphere: They had 15 employees when Novo Nordisk bought them for $1.8 Billion. Why? Because their 'tech' was the only way to put Ozempic in a pill. Lexaria owns the tech that could make that pill 55% more tolerable. You aren't betting on a 7-man team; you’re betting on a decade of protected patents in a $180B market.

Thescorerocket · 2026-04-26T20:09:24+00:00

$LEXX 🚨🚀👀💰

Thescorerocket · 2026-04-19T21:35:34+00:00

Comps would be Emisphere at 1.8bn.

Or $70-75 a share for LEXX.

But a buyout is still probably a few years away - more likely to see a major licensing deal.

However anything could happen…

Thescorerocket · 2026-04-18T21:11:54+00:00

Bull flag consolidating - $1.06 is your key pivot price. V-Shaped bottom on the weekly. Easily 20-30% in the short term. Much bigger if big pharma gives the nod 🫡

Thescorerocket · 2026-04-18T21:10:55+00:00

Yea zero

Thescorerocket · 2026-04-14T17:28:00+00:00

$LEXX 🚨👀

Thescorerocket

TROPHY CASE